Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.27 +0.37 (9.49%)
price chart
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Arena Pharmaceuticals (NASDAQ: ARNA ) held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline.
Related articles »  
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals (NASDAQ: ARNA ) have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech ...
Arena Pharmaceuticals - A Biotech Value Investment  Seeking Alpha (registration)
Investor's Watch List ´┐ŻArena Pharmaceuticals, Inc. (NASDAQ:ARNA), Image ...  Techsonian (press release)
Related articles »  
Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Arena Pharmaceuticals (NASDAQ: ARNA ) and Orexigen's (NASDAQ: OREX ) novel anti-obesity pills are among three drugs that the FDA has approved for use alongside diet and exercise to promote weight loss.
New anti-obesity drug is OK'd  Nashua Telegraph
Could new weight-loss drug Contrave be a weapon in obesity battle?  WRCB-TV
Related articles »  
Arena Down On The Back Of Weigh-Loss Drug Failure
However, Arena Pharmaceuticals Inc. (ARNA) seems to be moving in the opposite direction and has declined 31.6%. Arena has been unable to deliver on expectations of its weight-loss drug, Belviq.
FDA panel backs Novo Nordisk drug for obesity  Daily Item
FDA panel backs Novo Nordisk injection
Related articles »  
Don't Miss : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Caterpillar Inc ...
Contrave is a combination of two Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Vivus Inc. drugs that were approved by the FDA in 2012, ABC News reports, after having spent 13 years without approving any weight-loss medication.
Arena Pharmaceuticals Short Interest Down 5.7% in August (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) last posted its quarterly earnings results on Friday, August 1st. The company reported $0.03 earnings per share for the quarter, beating the analysts' consensus estimate of ($0.11) by $0.14. The company had revenue ...
Related articles »  
Orexigen Therapeutics Stumbles Off the Edge of a Cliff (ARNA, VVUS, OREX)
On the off chance you need a reminder, Orexigen Therapeutics, Inc. was greatly ballyhooed heading into last week's decision day from the Food and Drug Administration.
Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away  Seeking Alpha (registration)
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Obesity Pill Approval Fails to ...  BasicsMedia
Related articles »  
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary ...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, +0.26% today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog  NASDAQ
Related articles »  
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax ...
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. EXEL, +4.94% Arena Pharmaceuticals Inc. ARNA, -0.51% Novavax Inc. NVAX, +2.00% Dendreon Corporation DNDN, +0.68% and Amicus Therapeutics Inc. FOLD, +2.83% Free ...
Related articles »  
Belviq And Phentermine Study Awes Some Investors - Should It? (ARNA)
Like pretty much anyone invested in Arena Pharmaceuticals (NASDAQ:ARNA), I saw the snapshot of a poster relating to the study of a doctor which scripted Belviq and phentermine to patients.